RxDoctor Payments Data

Ahmed Alabbady, MD

Interventional Cardiology · Stony Point, NYNPI 1790030153

Payments from drug & device makers

$30,744in general payments, 2019–2025

Across 191 payments — averaging $160.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$23K
  • Abbott$3K
  • Abiomed$1K
  • Boston Scientific$943
  • Edwards Lifesciences$357
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$352
  • plus $2K from 19 others

What the payments were for

  • Grants$22,00072%
  • Travel & lodging$1,8606%
  • Food & beverage$6,81322%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,744 in reported general payments places this provider in the 65th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$279,504
Medicare patients
759
Services billed
2,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$91,075
EntrestoSacubitril/Valsartan28$35,333
FarxigaDapagliflozin Propanediol17$16,797
BrilintaTicagrelor12$13,443
Metoprolol Succinate138$2,057
Atorvastatin Calcium177$1,951
ClopidogrelClopidogrel Bisulfate74$797
Ezetimibe25$765
Rosuvastatin Calcium36$718
Valsartan31$612
Amlodipine Besylate50$551
Furosemide71$331
Hydralazine Hcl14$309
Losartan Potassium32$302
Labetalol Hcl11$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$172$91,07575 claims
NovartisEntresto$238$35,33328 claims
AstraZenecaFarxiga, Brilinta$196$30,24029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Stony Point

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →